MiRNA-Based Therapies for Lung Cancer: Opportunities and Challenges?

Han Yang; Yufang Liu; Longqing Chen; Juanjuan Zhao; Mengmeng Guo; Xu Zhao; Zhenke Wen; Zhixu He; Chao Chen; Lin Xu

doi:10.3390/biom13060877

MiRNA-Based Therapies for Lung Cancer: Opportunities and Challenges?

Biomolecules. 2023 May 23;13(6):877. doi: 10.3390/biom13060877.

Authors

Han Yang^{1

2}, Yufang Liu^{1

2}, Longqing Chen^{1

2}, Juanjuan Zhao^{1

2}, Mengmeng Guo^{1

2}, Xu Zhao^{1

2}, Zhenke Wen³, Zhixu He⁴, Chao Chen^{1

2}, Lin Xu^{1

2}

Affiliations

¹ Special Key Laboratory of Gene Detection and Therapy of Guizhou Province, Zunyi Medical University, Zunyi 563000, China.
² Department of Immunology, Zunyi Medical University, Zunyi 563000, China.
³ Institute of Biomedical Research, Soochow University, Soochow 563000, China.
⁴ Collaborative Innovation Center of Tissue Damage Repair and Regeneration Medicine of Zunyi Medical University, Zunyi 563000, China.

Abstract

Lung cancer is a commonly diagnosed cancer and the leading cause of cancer-related deaths, posing a serious health risk. Despite new advances in immune checkpoint and targeted therapies in recent years, the prognosis for lung cancer patients, especially those in advanced stages, remains poor. MicroRNAs (miRNAs) have been shown to modulate tumor development at multiple levels, and as such, miRNA mimics and molecules aimed at regulating miRNAs have shown promise in preclinical development. More importantly, miRNA-based therapies can also complement conventional chemoradiotherapy, immunotherapy, and targeted therapies to reverse drug resistance and increase the sensitivity of lung cancer cells. Furthermore, small interfering RNA (siRNA) and miRNA-based therapies have entered clinical trials and have shown favorable development prospects. Therefore, in this paper, we review recent advances in miRNA-based therapies in lung cancer treatment as well as adjuvant therapy and present the current state of clinical lung cancer treatment. We also discuss the challenges facing miRNA-based therapies in the clinical application of lung cancer treatment to provide new ideas for the development of novel lung cancer therapies.

Keywords: MiRNA-based therapy; chemoradiotherapy; immunotherapy; lung cancer; microRNAs; targeted therapy.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Combined Modality Therapy
Humans
Immunotherapy
Lung Neoplasms* / genetics
Lung Neoplasms* / pathology
Lung Neoplasms* / therapy
MicroRNAs* / genetics
MicroRNAs* / therapeutic use
RNA, Small Interfering

Substances

MicroRNAs
RNA, Small Interfering

Grants and funding

This work was supported by the National Natural Science Foundation of China (Grant No. 81960509, 82272812), the Project of the Guizhou Provincial Department of Science and Technology (Grant No. QKHZC-2020-4Y156), the Collaborative Innovation Center of the Chinese Ministry of Education (2020-39), the Project of the Department of Science and Technology of Zunyi (Grant No. ZKH-HZ-2021-193, ZYSKRPT-2020-6), and the Guizhou Provincial Department of Education (QJH-KY-2021-071) and the Graduate Research Fund of Zunyi Medical University (2023-ZYK-166).